*  US6415048B1 - Compositional analysis system - Google Patents
Derivatives of norbornanes having hydrocarbon side chains and perfume compositions containing the same ... Derivatives of norbornanes having hydrocarbon side chains and perfume compositions containing the same ...
  https://patents.google.com/patent/US6415048
*  Uncategorized - Page 2 - Chemical Communications Blog
... an interesting structure where two norbornanes share a pair of neighbouring edges so it looks like three interlaced norbornanes ...
  http://blogs.rsc.org/cc/category/uncategorized/page/2/?doing_wp_cron=1521608959.8752760887145996093750
*  2-Norbornyl cation - Wikipedia
It was also observed that the 2-exo- substituted norbornanes reacted 350 times faster than the corresponding endo- isomers. ...
  https://en.wikipedia.org/wiki/2-Norbornyl_cation
*  List of MeSH codes (D02) - Wikipedia
... norbornanes MeSH D02.455.849.575.781.234 --- bornanes MeSH D02.455.849.575.781.234.326 --- camphor MeSH D02.455.849.575.781.500 ...
  https://en.wikipedia.org/wiki/List_of_MeSH_codes_(D02)
*  Magnetic inequivalence - Wikipedia
Symmetrical norbornanes and similarly rigid compounds (e.g. 7-oxabicyclo[2.2.1]heptane) also show complex signals for the ...
  https://en.wikipedia.org/wiki/Magnetic_inequivalence
*  Blinatumomab - DrugBank
Blinatumomab is a BiTE-class (bi-specific T-cell engagers) constructed monoclonal antibody indicated for the treatment of Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). Blinatumomab is manufactured by Amgen Inc. and marketed under the brand Blincyto™. A full treatment regimen consisting of two cycles of four weeks each, is priced at $178 000 USD. Blinatumomab was approved in December 2014 under the FDA's accelerated approval program, which allows approval of a drug to treat a serious or life-threatening disease based on clinical data showing the drug has an effect on a surrogate endpoint reasonably likely to predict clinical benefit to patients.
  https://www.drugbank.ca/drugs/DB09052
*  3-diazobornane-2-one Summary Report | CureHunter
3-diazobornane-2-one: RN & N1 from CA Vol 91 Form Index; RN given refers to (1R)-isomer; structure in first source; cpd not in Chemline 7/19/83
  http://www.curehunter.com/public/keywordSummaryC024676-3-diazobornane-2-one.do
*  Maisto's Paste Summary Report | CureHunter
Maisto's Paste: a slowly resorbable root filling paste; composed of zinc oxide 14g, iodoform 42g, thymol 2g, camphorated chlorophenol 3cc, and anhydrous lanolin 0.5g
  http://www.curehunter.com/public/keywordSummaryC083357-Maisto-s-Paste.do
*  terephthalylidene dicamphor sulfonic acid - Ecamsule Summary Report | CureHunter
terephthalylidene dicamphor sulfonic acid: structure given in first source; abreviated as TDSA; FDA approved 2006 as component of Anthelios SX along with avobenzone and octocrylene
  http://www.curehunter.com/public/keywordSummaryC075352-terephthalylidene-dicamphor-sulfonic-acid-Ecamsule.do
*  Shane Hickey Home Page, University of South Australia
Synthesis and evaluation of cationic norbornanes as peptidomimetic antibacterial agents', Organic and biomolecular chemistry, ...
  http://people.unisa.edu.au/Shane.Hickey